Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Fitten, L. J. Articles by Fisher, A. Search for Related Content PubMed Citation Articles by Fitten, L. J. Articles by Fisher, A. Anxiety Disorders (General) Dementias (General)

Reduction of Motoric Agitation and Restlessness by AF102B and Tacrine in the Macaque

Received August 11, 1997; revised October 8, 1997; accepted January 30, 1998. From the U.S. Department of Veterans Affairs Sepulveda Medical Centers, Los Angeles, California. Address correspondence to Dr. Fitten, VAMC 116A-9, 16111 Plummer Street, Sepulveda, CA 91343; e-mail: jfitten{at}ucla.edu

The cholinesterase inhibitor tacrine (THA) and the M₁ muscarinic agonist AF102B (cevimeline), both reported to enhance cognition in animals and humans, were tested in 5 macaques for reduction of spontaneous, random movements. Monkeys were videotaped 1 hour after administration of normal saline vehicle, after low- and high-dose intramuscular AF102B, and after low- and high-dose oral THA. Two independent blind judges counted numbers of spontaneous movements made by each monkey over 12 consecutive 15-second segments for each drug condition. Both THA and AF102B reduced movement significantly at high doses without overt side effects, warranting further research on the agitation-reducing potential of cognition-enhancing cholinomimetic drugs.

Key Words: Agitation • AF102B • Tacrine • Animal Studies

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us